Carregant...
Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics
BACKGROUND: Although hydrochlorothiazide (HCTZ) is a well‐established first‐line antihypertensive in the United States, <50% of HCTZ treated patients achieve blood pressure (BP) control. Thus, identifying biomarkers that could predict the BP response to HCTZ is critically important. In this study...
Guardat en:
| Publicat a: | J Am Heart Assoc |
|---|---|
| Autors principals: | , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5778957/ https://ncbi.nlm.nih.gov/pubmed/29288159 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.117.006656 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|